Stay updated with breaking news from Aurelius Value. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Orso Partners founder was up 70 percent last year after calling the tech crash — and he’s got his eye on private equity.
A Maryland bank agreed to pay about $22.9 million to settle charges by two U.S. regulators that it failed to disclose tens of millions of dollars of loans to family trusts belonging to its former longtime chief executive officer.
Connecting the dots in a far-ranging probe.
Share this article Share this article NEW ORLEANS, April 16, 2021 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Vanda Pharmaceuticals Inc. (NasdaqGM: VNDA). On February 11, 2019, Aurelius Value reported that the Company was involved in an off-label promotion scheme in which its drug products, Fanapt and Hetlioz, were marketed to treat disorders for which the drugs were not FDA-approved, for example, promoting sales of Fanapt to children wi...
Health your username March 12, 2021 On Wednesday Judge Frederic Block of the Eastern District of New York partially denied a motion by Vanda Pharmaceuticals Inc. and four company executives to dismiss a class action that alleged that the defendants knowingly made statements that violated the Securities Exchange Act of 1934 in the marketing of Vanda drugs. Lead plaintiff Kenneth Gordon argued that biopharmaceutical company Vanda and officials Mihael H. Polymeropoulos, James P. Kelly, Gian Piero Reverberi, and Thomas E. Gibbs made materially misleading and false statements and omissions in the...